RenovoRx, Inc. RNXT
Set alert
1.33 USD -0.16 -10.74%
At close · Oct 30
1.33 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
1.34 Day range 1.50
0.733 52-week range 2.52
- YTD
- +58.33%
- 1 year
- +31.68%
- Open
- 1.49
- Prev close
- 1.49
- Mkt cap
- 60.02M
- Vol
- 376.39K
- Avg vol
- 810.88K
- EPS
- -0.31
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.34
- High
- 1.50
- Forward P/E
- -3.10
- Beta
- 0.99
- Short ratio
- 3.43
- Inst. own
- 8.18%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 1.14
- 200-d avg
- 1.18
- 1y target
- 5.50
Key statistics
- Market cap
- 30.48M
- Enterprise value
- 14.40M
- Trailing P/E
- 0.00
- Forward P/E
- -3.10
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -0.58
- Beta
- 0.99
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.62M
- Total cash
- 11.74M
- Total debt
- 0
- Return on equity
- -155.12%
- Shares outstanding
- 24.00M
- Short % of float
- 0.31%
- 50-day average
- 1.14
- 200-day average
- 1.18
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 5.50 +313.5% upside
Now 1.33
- Target (low)
- 3.50
- Target (mean)
- 5.50
- Target (high)
- 9.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.12.
Financials — quick view
RNXT Revenue — quarterly 909.00K
RNXT Net income — quarterly -2.91M
RNXT EPS — quarterly -0.06
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.12 | -0.10 | +0.02 | +16.67% |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.10 | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | -0.07 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -0.17 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | Ascendiant Capital | main | Buy | Buy |
| Sep 12, 2024 | Ascendiant Capital | main | Buy | Buy |
| Jun 17, 2024 | Ascendiant Capital | init | — | Buy |
| Feb 2, 2024 | Alliance Global Partners | init | — | Buy |
| Nov 15, 2023 | Maxim Group | down | Buy | Hold |
| Aug 18, 2023 | Roth MKM | main | Buy | Buy |
About RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- renovorx.com
News
- RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
- RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
- 12 Health Care Stocks Moving In Friday's After-Market Session
- RenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP Study
- RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
- RenovoRx Announces Publication Of Peer-Reviewed Case Series In Case Reports In Oncology From Researchers At Hackensack Meridian Health’s Jersey Shore University Medical Center
- RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
- RenovoRx, Inc. (NASDAQ:RNXT) Stock Short Interest Jumps 55.7%
- RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
- Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5
Your note
Sign in to keep a note on RNXT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGAH RAMTIN M.D. | Officer and Director | Purchase | Jan 25, 2024 | 47,460 |
| BAGAI SHAUN R. | Chief Executive Officer | Purchase | Jan 25, 2024 | 292,540 |
| MACFARLANE KIRSTEN ANGELA | Director | Purchase | Jan 25, 2024 | 40,983 |
| MARTON LAURENCE | Director | Purchase | Jan 25, 2024 | 33,634 |
| NELMS ANGELA GILL | Chief Operating Officer | Purchase | Oct 2, 2023 | 1,100 |
| SPIEGEL ROBERT J | Director | Purchase | Jan 25, 2024 | 40,983 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bank of Montreal /CAN/ | 4.06% | 975,000 | 1.24M | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 1.31% | 315,192 | 400.29K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.97% | 232,937 | 295.83K | Sep 29, 2024 |
| Nixon Peabody Trust Company | 0.40% | 97,165 | 123.40K | Sep 29, 2024 |
| Millennium Management Llc | 0.34% | 82,353 | 104.59K | Sep 29, 2024 |
| Vanguard Group Inc | 0.24% | 56,737 | 72.06K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.57% | 137,402 | 174.50K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.24% | 56,737 | 72.06K | Sep 29, 2024 |
| Schwab Capital Trust-Total Stock Market Index Fund | 0.21% | 49,232 | 62.52K | Jul 30, 2024 |
| Fidelity Total Market Index Fund | 0.20% | 47,275 | 60.04K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 32,380 | 41.12K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 3,794 | 4.82K | Oct 30, 2024 |